mTORC1 pathway with different clinical implications

Overview of attention for article published in Breast Cancer Research, April 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (69th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 7 X users

f1000: 1 research highlight platform

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 83 Mendeley

Summary X Research highlights Dimensions citations

So far, Altmetric has seen 8 X posts from 7 X users, with an upper bound of 4,540 followers.

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications https://t.co/pvoXJxA9db

19 Feb 2021

Reply Repost Favourite

18 Jul 2020

Reply Repost Favourite

RT @fedenichetti: Everolimus vs Alpelisib, who wins? In the #COVID19 days, our work on cancer research goes on! @BioMedCentral https://t.co…

09 Apr 2020

Reply Repost Favourite

08 Apr 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.